Streetbeat News

Stock Prices

KKR

KKR & Co's short percent of float has risen 19.34% since its last report, with 16.21 million shares sold short, which is 2.53% of all regular shares available for trading. It would take traders 4.69 days to cover their short positions on average. An increase in short interest can signal that investors have become more bearish. However, KKR & Co's peer group average for short interest as a percentage of float is 2.96%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 4:30 pm

NUE

STLD

ZEUS

Shares of steel stocks are trading lower in sympathy with Nucor, which issued weak Q3 guidance. Steel Dynamics (STLD) and Olympic Steel (ZEUS) may also be affected.

Portfolio Pulse from Benzinga Newsdesk

September 15, 2023 | 4:27 pm

F

GM

STLA

TSLA

Members of the United Auto Workers union have gone on strike, affecting Ford Motor Company, General Motors Company, and Stellantis. Analyst Daniel Ives suggests that Tesla, which is not unionized, could benefit from this situation. The strike could potentially increase costs and delay the Big 3 automakers' transition to electric vehicles, giving Tesla an advantage.

Portfolio Pulse from Erica Kollmann

September 15, 2023 | 4:27 pm

AGRI

AgriFORCE Growing Systems' shares are trading higher on abnormally-high volume. There is no company-specific news to justify the price action.

Portfolio Pulse from Benzinga Newsdesk

September 15, 2023 | 4:24 pm

MRNA

A significant amount of unusual options activity has been observed for Moderna (NASDAQ:MRNA), indicating a potential upcoming change in the stock's performance. The sentiment among these big-money traders is split evenly between bullish and bearish. The price range targeted by these traders over the last three months is from $70.0 to $230.0. Argus Research has maintained their Buy rating on Moderna, with a price target of $140.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 4:18 pm

ETN

A significant bearish stance has been taken on Eaton Corp (NYSE:ETN) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is split between 40% bullish and 60% bearish. The whales have been targeting a price range from $195.0 to $270.0 for Eaton Corp over the last 3 months. The current price of ETN is down -2.39% at $216.85. HSBC has maintained their Hold rating on Eaton Corp with a price target of $210.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 4:18 pm

DXCM

PODD

TNDM

Shares of diabetes and glucose monitoring companies are trading lower following a report that Apple is developing a glucose tracker. Raymond James also cut its price targets on Dexcom and Insulet.

Portfolio Pulse from Benzinga Newsdesk

September 15, 2023 | 4:18 pm

ADBE

Adobe Inc's shares dipped nearly 5% despite beating Q3 earnings estimates. The company reported earnings of $4.09 per share, beating estimates of $3.98, and quarterly sales of $4.89 billion, slightly above the consensus estimate of $4.87 billion. Analysts from Goldman Sachs, Piper Sandler, RBC Capital Markets, and BMO Capital Markets remain bullish on Adobe, citing factors such as its positioning to benefit from AI, upcoming price hikes for certain Creative Cloud plans, and the potential boost from upcoming price increases.

Portfolio Pulse from AJ Fabino

September 15, 2023 | 4:16 pm

SONY

Sony Group Corp (NYSE:SONY) hosted a State of Play event on Sept. 14, showcasing upcoming titles for PlayStation 5 and PlayStation 4. Standout games and announcements included Resident Evil 4 VR, Final Fantasy VII Rebirth, and new PS5 plates and controller colors. The event also featured a price hike for PlayStation Plus following a similar increase for Xbox Game Pass.

Portfolio Pulse from Franca Quarneti

September 15, 2023 | 4:09 pm

CMND

UK-based venture studio Beckley Waves has raised $3.3 million in a funding round to expand safe and legal access to psychedelic therapies. The round was oversubscribed by 10% and included participation from several family and VC mission-aligned offices. The funds will be used for strategic investments into selected early-stage teams. In other news, Israeli biotech company Clearmind Medicine (NASDAQ:CMND) is pricing its US-only public offering, expecting to raise approximately $2.25 million. The offering consists of 7.5 million common shares and pre-funded warrants, and 7.5 million common warrants.

Portfolio Pulse from Lara Goldstein

September 15, 2023 | 4:09 pm